Authors: Greenberg, HE Wissel, P Barrett, J Barchowsky, A Gould, R Farrell, D Panebianco, D Hand, E Gillen, L Goldberg, MR Bjornsson, TD

Citation: He. Greenberg et al., Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist,in healthy volunteers, J CLIN PHAR, 40(5), 2000, pp. 496-507

Authors: Greenberg, HE Gottesdiener, K Huntington, M Wong, P Larson, P Wildonger, L Gillen, L Dorval, E Waldman, SA

Citation: He. Greenberg et al., A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX (R)), did not alter theantiplatelet effects of low-dose aspirin in healthy volunteers, J CLIN PHAR, 40(12), 2000, pp. 1509-1515

Authors: Prueksaritanont, T Vega, JM Rogers, JD Gagliano, K Greenberg, HE Gillen, L Brucker, MJ McLoughlin, D Wong, PH Waldman, SA

Citation: T. Prueksaritanont et al., Simvastatin does not affect CYP3A activity, quantified by the erythromycinbreath test and oral midazolam pharmacokinetics, in healthy male subjects, J CLIN PHAR, 40(11), 2000, pp. 1274-1279

Authors: McCrea, J Prueksaritanont, T Gertz, BJ Carides, A Gillen, L Antonello, S Brucker, MJ Miller-Stein, C Osborne, B Waldman, S

Citation: J. Mccrea et al., Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity, J CLIN PHAR, 39(12), 1999, pp. 1212-1220

Authors: McCrea, JB Cribb, A Rushmore, T Osborne, B Gillen, L Lo, MW Waldman, S Bjornsson, T Spielberg, S Goldberg, MR

Citation: Jb. Mccrea et al., Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174, CLIN PHARM, 65(3), 1999, pp. 348-352